Results 41 to 50 of about 39,918 (251)

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Implications of apixaban for dental treatments [PDF]

, 2016
Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. Recently, new oral anticoagulants have been introduced as alternatives to warfarin and acenocoumarol.
Albaladejo Martínez, Alberto, Curto Aguilera, Adrián   +1 more
core   +1 more source

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration

Frontiers in Veterinary Science, 2018
Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa, Marjory B. Brooks, Thomas Divers, Sally Ness, Ingvild Birschmann, Mark G. Papich, Tracy Stokol   +6 more
doaj   +1 more source

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source

Extended thromboprophylaxis with betrixaban in acutely ill medical patients [PDF]

, 2016
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
. Lodigiani, M, : W. Ageno, I, Cerveri, A., Cohen, Alexander T, De Pellegrin, D, D’Angelo, A, Gibson, C. Michael, Gold, Alex, Goldhaber, Samuel Z., Harrington, Robert A., Hernandez, Adrian F., Hull, Russell D., Imberti, R., Investigators, Italy (261 patients, 19 sites, Landolfi, G, LEMBO, Giuseppe, Luisetti, M., Wiens, Brian L.   +18 more
core   +1 more source

Clinical pharmacology consultations and their implementation in clinical decision making

British Journal of Clinical Pharmacology, EarlyView.
Aims One of the key roles of clinical pharmacologists is to work as consultants for other medical specialties. We wanted to investigate the characteristics of clinical pharmacology consultations, compare the types of consultations from different specialties, and evaluate how well the recommendations given were followed.
Mirjam Kauppila, Janne T. Backman, Outi Lapatto‐Reiniluoto   +2 more
wiley   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients [PDF]

, 2011
The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term ...
, Goldhaber, Samuel Z, Haas, Sylvia K, Kakkar, Ajay K, Knabb, Robert M, Leizorovicz, Alain, Merli, Geno, Pedersen, Court, Weitz, Jeffrey I   +8 more
core   +3 more sources

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa, Job Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Cesarman‐Maus   +6 more
doaj   +1 more source